CalciMedica, Inc.
Clinical trials sponsored by CalciMedica, Inc., explained in plain language.
Clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibitors.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Experimental drug auxora tested in critical COVID-19 lung patients
Disease control Stopped earlyThis small Phase 2 trial tested an experimental drug called Auxora in 10 patients with critical COVID-19 pneumonia who were on ventilators. The goal was to see how the drug affected immune cells in the lungs and to check its safety. The study was terminated early, so results are …
Phase 2 • Sponsor: CalciMedica, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug aimed at Kidney-Lung crisis shows promise in trial
Disease control Stopped earlyThis study tests an experimental drug called Auxora in 150 adults with acute kidney injury and breathing failure. Patients receive either Auxora or a placebo daily for five days. The goal is to see if Auxora helps patients survive, breathe without a machine, and avoid kidney dial…
Phase 2 • Sponsor: CalciMedica, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC